Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors and Immunomodulatory Agents: A Real-Life Multicenter Analysis.

Autor:	Atas U; Akdeniz University, Faculty of Medicine, Division of Hematology, Antalya, Türkiye.; Health Sciences University, Antalya Training and Research Hospital, Division of Hematology, Antalya, Türkiye., Salim O; Akdeniz University, Faculty of Medicine, Division of Hematology, Antalya, Türkiye., Iltar U; Akdeniz University, Faculty of Medicine, Division of Hematology, Antalya, Türkiye., Yucel OK; Akdeniz University, Faculty of Medicine, Division of Hematology, Antalya, Türkiye., Kucukdiler Eroglu AH; Aydin Adnan Menderes University, Faculty of Medicine, Division of Hematology, Aydın, Türkiye., Aslan V; Health Sciences University, Antalya Training and Research Hospital, Division of Hematology, Antalya, Türkiye., Yildirim M; Health Sciences University, Ankara Gulhane Training and Research Hospital, Division of Hematology, Ankara, Türkiye., Dedeoglu O; Marmara University, Faculty of Medicine, Division of Hematology, İstanbul, Türkiye., Secilmis S; Health Sciences University, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Division of Hematology, Ankara, Türkiye., Ulas T; Health Sciences University, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Division of Hematology, Ankara, Türkiye., Deveci B; Antalya Bilim University, Antalya, Türkiye., Karaman Gulsaran S; Trakya University, Faculty of Medicine, Division of Hematology, Edirne, Türkiye., Geduk A; Kocaeli University, Faculty of Medicine, Division of Hematology, Kocaeli, Türkiye., Yaman F; Eskisehir Osmangazi University, Faculty of Medicine, Division of Hematology, Eskişehir, Türkiye., Pinar IE; Bursa Uludag University, Faculty of Medicine, Division of Hematology, Bursa, Türkiye., Maral S; Health Sciences University, Diskapi Yildirim Beyazit Training and Research Hospital, Division of Hematology, Ankara, Türkiye., Sarici A; Inonu University, Faculty of Medicine, Division of Hematology, Malatya, Türkiye., Celik S; Erciyes University, Faculty of Medicine, Division of Hematology, Kayseri, Türkiye., Ogul H; Pamukkale University, Faculty of Medicine, Division of Hematology, Denizli, Türkiye., Gulkan Ozkan S; Yeditepe University, Faculty of Medicine, Division of Hematology, İstanbul, Türkiye., Gemici A; Istanbul Medipol University, Medipol Mega Hospital, Division of Hematology, İstanbul, Türkiye., Gunes AK; Ankara City Hospital, Division of Hematology, Ankara, Türkiye., Tombak A; Mersin University, Faculty of Medicine, Division of Hematology, Mersin, Türkiye., Yavasoglu I; Aydin Adnan Menderes University, Faculty of Medicine, Division of Hematology, Aydın, Türkiye., Karakus V; Health Sciences University, Antalya Training and Research Hospital, Division of Hematology, Antalya, Türkiye., Comert M; Health Sciences University, Ankara Gulhane Training and Research Hospital, Division of Hematology, Ankara, Türkiye., Toptas T; Marmara University, Faculty of Medicine, Division of Hematology, İstanbul, Türkiye., Dal MS; Health Sciences University, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Division of Hematology, Ankara, Türkiye., Saba R; Antalya Bilim University, Antalya, Türkiye., Kirgizlar HO; Trakya University, Faculty of Medicine, Division of Hematology, Edirne, Türkiye., Mehtap O; Kocaeli University, Faculty of Medicine, Division of Hematology, Kocaeli, Türkiye., Gunduz E; Eskisehir Osmangazi University, Faculty of Medicine, Division of Hematology, Eskişehir, Türkiye., Ozkalemkas F; Bursa Uludag University, Faculty of Medicine, Division of Hematology, Bursa, Türkiye., Albayrak M; Health Sciences University, Diskapi Yildirim Beyazit Training and Research Hospital, Division of Hematology, Ankara, Türkiye., Berber I; Inonu University, Faculty of Medicine, Division of Hematology, Malatya, Türkiye., Keklik M; Erciyes University, Faculty of Medicine, Division of Hematology, Kayseri, Türkiye., Guler N; Pamukkale University, Faculty of Medicine, Division of Hematology, Denizli, Türkiye., Ozkan HA; Yeditepe University, Faculty of Medicine, Division of Hematology, İstanbul, Türkiye., Sevindik OG; Istanbul Medipol University, Medipol Mega Hospital, Division of Hematology, İstanbul, Türkiye., Bolaman Z; Aydin Adnan Menderes University, Faculty of Medicine, Division of Hematology, Aydın, Türkiye., Kurtoglu E; Health Sciences University, Antalya Training and Research Hospital, Division of Hematology, Antalya, Türkiye., Ayli M; Health Sciences University, Ankara Gulhane Training and Research Hospital, Division of Hematology, Ankara, Türkiye., Firatli Tuglular T; Marmara University, Faculty of Medicine, Division of Hematology, İstanbul, Türkiye., Altuntas F; Health Sciences University, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Division of Hematology, Ankara, Türkiye., Undar L; Akdeniz University, Faculty of Medicine, Division of Hematology, Antalya, Türkiye.
Jazyk:	angličtina
Zdroj:	Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2024 Nov 06. Date of Electronic Publication: 2024 Nov 06.
DOI:	10.4274/tjh.galenos.2024.2024.0450
Abstrakt:	Objective: In this study, we aimed to obtain real-life data on the use of antimyeloma agents, which significantly increase overall survival (OS) in multiple myeloma (MM) patients, in primary plasma cell leukemia (pPCL) patients with a poor prognosis. Materials and Methods: Data from 53 patients who were diagnosed with pPCL between 2011-2020 and who used at least one proteasome inhibitor (PI) and/or immunomodulatory (IMID) agent were analyzed retrospectively. Depending on the year of pPCL diagnosis, 20% leukocytes or ≥2×109/L plasma cells in the peripheral blood were used. Results: The median age of the patients was 58 years, and 23 (43.4%) patients were over 65 years of age. For first-line treatment, PI or IMID alone was used in 31 (58.5%) patients, and PI and IMID were used simultaneously in 15 (28.3%) patients. Additionally, 21 (39.6%) patients received transplantation, and 13 (24.5%) patients received maintenance treatment. The median progression-free survival was 4 (1-42) months. When patients whose primary disease was refractory to first-line therapy were excluded, the duration of treatment was 6.5 months. The median OS was 15 months, with a median follow-up of 15 months. Only 7 (13.2%) of the patients were alive at the last follow-up visit. Those with higher beta-2 microglobulin levels and ISS stage 3 and nontransplant patients receiving first-line treatment had shorter OS (p=0.005, p=0.02 and p=0.008, respectively). Otherwise, the concomitant use of PIs and IMIDs, the addition of chemotherapy to induction therapy, and the response to induction therapy or maintenance therapy did not affect OS. Conclusion: In our study, as in previous similar studies, we could not see the increased survival trend in pPCL which is observed in MM. New studies are needed for pPCL patients, which is likely to increase with the new diagnostic criteria, based on current agents and information in MM.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu